CADRONATE 150MG

Indications

• Osteoporosis in postmenopausal women
• Prevention of osteoporosis in women at high risk
• Paget's disease of bone
• Bone metastases from breast cancer

Dosage

Children: Not established; refer to BNF for Children for guidance.

Adults: Refer to BNF for specific dosing information based on condition and formulation.

Mechanism of action

Ibandronic acid inhibits the activity of osteoclasts, the cells responsible for bone resorption. It binds to hydroxyapatite in bone, leading to a decrease in osteoclast recruitment and activity. This results in reduced bone turnover and an increase in bone mass. The drug's action also involves the inhibition of farnesyl pyrophosphate synthase, an enzyme involved in the mevalonate pathway, which is crucial for osteoclast function.

Pharmacodynamics

The pharmacodynamics of ibandronic acid involve its ability to alter bone remodeling processes. By inhibiting osteoclast-mediated bone resorption, ibandronic acid leads to an increase in bone mineral density over time. Clinically, this translates to a lower incidence of vertebral and non-vertebral fractures in patients with osteoporosis. Its effects are dose-dependent, with higher doses providing greater efficacy in bone density improvement.

Pharmacokinetics

Ibandronic acid has a low oral bioavailability of approximately 0.6% due to poor absorption from the gastrointestinal tract. It is predominantly eliminated via the kidneys, with a half-life of approximately 10 to 60 hours depending on the formulation and route of administration. The drug is primarily distributed to bone and has a high affinity for mineralized tissues, where it remains for extended periods, contributing to its long-term effects on bone health. Renal function should be monitored, as impaired renal function can affect drug clearance.

Contra-indications

• Hypersensitivity to ibandronic acid or any component of the formulation
• Hypocalcemia
• Severe renal impairment (creatinine clearance < 30 mL/min)

Adverse effects

• Gastrointestinal disturbances (nausea, abdominal pain, dyspepsia)
• Musculoskeletal pain
• Osteonecrosis of the jaw
• Esophageal irritation or ulceration
• Hypocalcemia
• Flu-like symptoms
• Dermatological reactions (rash, itching)

Interactions

• Antacids containing aluminum, calcium, or magnesium may reduce ibandronic acid absorption
• Other bisphosphonates may have additive effects
• NSAIDs may increase the risk of gastrointestinal adverse effects

Precautions

• Use with caution in patients with a history of gastrointestinal disease
• Ensure adequate calcium and vitamin D levels before initiation
• Monitor renal function periodically during treatment
• Consider dental examination prior to initiation, especially in patients with risk factors for osteonecrosis of the jaw

Pregnancy

Ibandronic acid is not recommended during pregnancy due to potential harm to the fetus. It should only be used if the potential benefit justifies the risk.

Breast-feeding

Ibandronic acid is excreted in breast milk; however, the effects on a nursing infant are unknown. Caution is advised.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Tablets (150 mg)
• Intravenous injection (3 mg/3 mL)

Indications

• Cancer (various types)
• Rheumatoid arthritis
• Multiple sclerosis
• Inflammatory bowel disease
• Psoriasis
• Hypercholesterolemia
• Infectious diseases (e.g., COVID-19)

Dosage

Children: Refer to the BNF for Children for paediatric dosing information, as it varies based on the specific monoclonal antibody and the condition being treated.

Adults: Refer to the specific monoclonal antibody product information for adult dosage, as it varies based on indication and specific agent used.

Mechanism of action

Monoclonal antibodies work by binding to specific proteins on the surface of cells. This binding can block the activity of certain proteins, mark cells for destruction by the immune system, or deliver cytotoxic agents directly to target cells. The mechanism of action varies depending on the specific monoclonal antibody but often involves modulation of immune response, inhibition of cell proliferation, and induction of apoptotic pathways.

Pharmacodynamics

The pharmacodynamics of monoclonal antibodies is primarily characterized by their specificity and affinity for targeted antigens. This leads to a variety of effects, including neutralization of pathogens, blockade of receptor-ligand interactions, and antibody-dependent cellular cytotoxicity. The clinical effects depend on the disease being treated and the specific antibody's action, such as inducing tumor regression in cancer or reducing inflammation in autoimmune diseases.

Pharmacokinetics

Monoclonal antibodies typically have a long half-life, allowing for less frequent dosing. They are generally administered intravenously or subcutaneously, with absorption and distribution influenced by the antibody's size and charge. The elimination occurs primarily through proteolytic degradation and intracellular recycling. Factors such as patient-specific variables, including immunogenicity and the presence of antibodies against the monoclonal antibody, can impact pharmacokinetics.

Interactions

• abatacept+monoclonalantibodies: Severe (increases risk of generalised infection (possibly life-threatening))
• anakinra+monoclonalantibodies: Severe (increases risk of generalised infection (possibly life-threatening))
• anthracyclines+monoclonalantibodies: Severe (increases risk of cardiotoxicity)
• filgotinib+monoclonalantibodies: Severe (increases risk of immunosuppression)
• monoclonalantibodies+fingolimod: Severe (increases risk of generalised infection (possibly life-threatening))
• normal immunoglobulin+monoclonalantibodies: Severe (affects effects)
• monoclonalantibodies+ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• monoclonalantibodies+siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• monoclonalantibodies+vemurafenib: Severe (increases risk of hepatotoxicity)
• monoclonalantibodies+aminophylline: Moderate (decreases exposure)

Indications

• Hyponatremia
• Electrolyte imbalance
• Fluid replacement therapy
• Management of certain types of metabolic alkalosis

Dosage

Children: Dosage should be determined based on the clinical condition and should follow the guidelines provided in the BNF for Children.

Adults: Dosage varies depending on the condition being treated. Refer to specific guidelines for the appropriate dosage in individual cases.

Mechanism of action

Monosodium acts as an electrolyte, helping to maintain fluid balance and osmotic pressure in the body. It dissociates in solution to release sodium ions, which are critical for the proper functioning of cells, including nerve and muscle cells. Sodium ions play a crucial role in generating action potentials in neurons and muscle fibers.

Pharmacodynamics

Sodium is vital for maintaining homeostasis and is involved in various physiological processes. It contributes to the regulation of blood pressure, volume, and pH balance. The body regulates sodium levels through hormonal control, primarily via aldosterone, which promotes sodium reabsorption in the kidneys.

Pharmacokinetics

Sodium is absorbed in the gastrointestinal tract and is distributed throughout the body's extracellular fluid. The kidneys are primarily responsible for sodium excretion, and they adjust sodium reabsorption according to the body's needs. The half-life of sodium is not typically defined as it is continuously regulated by the body’s homeostatic mechanisms.